Cervicovaginal secretions
Phase 1Small molecule
Cervicovaginal secretions is one of 18 small molecule programs targeting Bacterial Vaginosis. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
65 competitors in Bacterial Vaginosis
#DrugCompanyPhaseTrials
1Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
N-Acetyl Cyteien
SStanford University
Approved
Lactobacillus Acidophilus
UUniversiteit Antwerpen
Approved
Tindamax
MMission Pharmacal
Phase 3
Lactoferrin
UUniversità degli Studi di Ferrara
Phase 3
Conventional
PPopulation Health Research Institute
Phase 3
Lactoserum
SanofiApproved
Longidaza
NNPO Petrovax
Approved
Xifaxan
SSalix
Phase 2
Metronidazole Suppositories
PPeking University Shenzhen Hospital
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cervicovaginal secretions. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- JJohns Hopkins University